Chinese biopharma firms listed in U.S. SEC audit crisis
HONG KONG – A recent ruling by the U.S. SEC banning Big Four accounting firms from performing audits linked to China could spell trouble for Chinese biopharmaceutical companies listed in the U.S. The ban is not yet in force pending an appeal.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter